Viral vector nanocapsule for targeting gene therapy and its preparation

Patent metadata

Field	Value
Publication number	US-10179112-B2
Application number	US-201314651945-A
Country	US
Kind code	B2
Filing date	Dec 16, 2013
Priority date	Dec 14, 2012
Publication date	Jan 15, 2019
Grant date	Jan 15, 2019

Abstract

The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies.

First claim

What is claimed is:

1. A composition of matter comprising:
a viral vector having an envelope and a first tissue tropism;
a degradable polymer shell encapsulating the viral vector, wherein:
the degradable polymer shell is formed by in situ polymerization on the viral vector envelope so as to encapsulate the viral vector;
encapsulation of the viral vector by the degradable polymer shell decreases the first tissue tropism; and
the degradable polymer shell is crosslinked; and

a targeting agent coupled to the degradable polymer shell.

2. The composition of claim 1 , wherein the viral vector is a Vesicular stomatitis Indiana virus G protein (VSV-G) pseudotyped lentiviral vector.

3. The composition of claim 1 , wherein the cross-linked degradable polymer shell comprises N-acryloxysuccinimide (NAS), acrylamide, and glycidyl methacrylate (GMA).

4. The composition of claim 1 , wherein the crosslinked polymer shell degrades in an acidic environment, thereby releasing the viral vector from the polymer shell.

5. The composition of claim 1 , wherein the targeting agent is an antibody.

6. The composition of claim 1 , wherein the targeting agent binds a peripheral blood mononuclear cell.

7. The composition of any one of claims 1 - 6 , wherein the targeting agent is a cyclic arginine-glycine-aspartic acid (cRGD), said cRGB having an affinity to an α v β 3 integrin on a tumor cell.

8. The composition of claim 2 , wherein the cross-linked degradable polymer shell comprises N-acryloxysuccinimide (NAS).

9. The composition of claim 2 , wherein the cross-linked degradable polymer shell comprises acrylamide.

10. The composition of claim 2 , wherein the targeting agent is an antibody.

11. The composition of claim 2 , wherein the targeting agent binds a peripheral blood mononuclear cell.

12. A composition of matter comprising:
a viral vector having an envelope;
a degradable polymer shell encapsulating the viral vector, wherein:
the viral vector exhibits a first tropism when encapsulated by the degradable polymer shell; and
the viral vector exhibits a second tropism when the degradable polymer shell is degraded;
the degradable polymer shell is formed on the viral vector by:
(a) combining the viral vector with a polymerizable monomer and a crosslinking agent such that the polymerizable monomer and the crosslinking agent adsorb to surfaces of the envelope; and
(b) polymerizing the polymerizable monomers and the crosslinking agent in situ on surfaces of the envelope so as to form a degradable polymer shell that:
(i) is crosslinked;
(ii) comprises a polymeric network that surrounds the envelope and that encapsulates the envelope so as to form a polymeric nanocapsule; and

a targeting agent coupled to the degradable polymer shell.

13. The composition of claim 12 , wherein the viral vector is a Vesicular stomatitis Indiana virus G protein (VSV-G) pseudotyped lentiviral vector.

14. The composition of claim 13 , wherein the crosslinked polymer shell temporarily shields a native binding ability of the Vesicular stomatitis Indiana virus G protein (VSV-G) pseudotyped lentiviral vector.

15. The composition of claim 14 , wherein the degradable polymer shell degrades at a pH below 6.0, thereby releasing the viral vector from the degradable polymer shell.

16. The composition of claim 15 , wherein a lysine residue on the envelope is coupled to the degradable polymer shell.

17. A composition of matter comprising:
a viral vector having an envelope and a first tissue tropism;
a degradable polymer shell encapsulating the viral vector, wherein:
the degradable polymer shell is formed by in situ polymerization on the viral vector envelope so as to encapsulate the viral vector and mask the first tissue tropism; and
the degradable polymer shell is crosslinked; and
a targeting agent coupled to the degradable polymer shell.

Assignees

• Univ California
• Lu Yunfeng
• Yan Ming
• Chen Irvin S Y
• Liang Min

Inventors

• Lu Yunfeng
• Yan Ming
• Chen Irvin S Y
• Liang Min

Classifications

• A61K9/5184

  Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127) · CPC title

• C12N2810/80

  from vertebrates · CPC title

• A61K9/5192

  Processes · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61K47/6925

  the form being a microcapsule, nanocapsule, microbubble or nanobubble · CPC title